🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Travere Therapeutics, Inc. (TVTX)
NASDAQ: TVTX · Real-Time Price · USD
48.06
-0.24 (-0.50%)
Nov 20, 2026, 2:08 PM EST - Market open
← View all transcripts

Jefferies Global Healthcare Conference

Nov 17, 2026

Summary

Q3 delivered 1,932 FILSPARI patient start forms and $200M in net revenue, while management cited early penetration across IgAN and FSGS. The $3B annual sales target by 2033 is supported by broad kidney-disease opportunities, extended patents and pipeline progress.

Maury Raycroft
Biotech Analyst, Jefferies

Morning, everyone. My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies. It's with great pleasure that I'd like to welcome the Travere Therapeutics team. We've got Peter Heerma, the Chief Commercial Officer, and Chris Cline, the CFO. Thanks so much for joining us today.

Chris Cline
CFO, Travere Therapeutics

Thanks for having us, Maury. It's great to be here.

Maury Raycroft
Biotech Analyst, Jefferies

We're going to do fireside chat format, so maybe for those who are new to the story, if you want to give a brief intro to Travere.

Chris Cline
CFO, Travere Therapeutics

Sure. Well, first off, thank you again for having us here. It's great to be here in London to be able to talk about Travere with all of you. Peter and I will be making forward-looking statements, so please make sure you reference our full risk factors and disclosures on Form 10-K and 10-Q filed with the SEC. At Travere, we are exclusively focused on delivering life-changing therapies to people living with rare diseases. We do that in two ways. First, on the commercial side, we've got multiple approved products, the latest being FILSPARI, which is a dual endothelin angiotensin receptor antagonist that is indicated for the treatment of IgA nephropathy and FSGS, or focal segmental glomerulosclerosis, for patients without active nephrotic syndrome. These are two of the most progressive rare kidney diseases out there.

Peter and his team, and I know we will talk a little bit about it, have been doing an excellent job of being able to reach patients and create a new foundation of care in IgA nephropathy and having a very successful launch in the early days here in FSGS. We also have a very exciting pipeline that is centered around two assets that have best-in-class potential. The first one is pegtibatinase, which is an enzyme replacement therapy for something called classical homocystinuria, a rare metabolic disease. There we are focused on completing enrollment in our ongoing phase III HARMONY study, and we are expecting that the data from that, should they come out the way that we expect them to, would be able to support a BLA submission and potentially lead to the first disease-modifying therapy approved for classical homocystinuria.

The other program in our pipeline is newer to us, civorebrutinib. This is a next-generation BTK inhibitor that we in-licensed earlier this year. Here we think we have the potential for a pipeline in a product and really to have a best-in-class BTK inhibitor that can be effective for multiple immune-mediated rare kidney diseases. So, very exciting time and a lot to talk about today with you.

Maury Raycroft
Biotech Analyst, Jefferies

Great. Yeah, it is a great intro, and you have got the commercial launch underway for IgAN and FSGS. Just had third quarter earnings. Maybe just go through some of the key highlights from third quarter.

Peter Heerma
Chief Commercial Officer, Travere Therapeutics

Yeah, happy to take that one, Maury. First of all, I would say very strong quarter again. Nearly 2,000 new patient start forms, 1,932 across IgA nephropathy and FSGS. Also from a revenue perspective, very strong quarter, $200 million in net revenue. So, strong continued demand as well as revenue.

Maury Raycroft
Biotech Analyst, Jefferies

Right. Yeah. You mentioned that two-thirds of FSGS prescribers have still treated only one patient. What is keeping those physicians from prescribing to a second or third patient, and what needs to happen for broader adoption?

Peter Heerma
Chief Commercial Officer, Travere Therapeutics

Yeah, I would say two-thirds physician having one patient so far is very typical in the launch. You have to realize we are still early in the launch. It is now seven months since we had the approval. What often happens is that physician have a sort of patient in mind that they want to treat with a newly approved product. Often the most progressive patient, and based on the experience that they have, they will start a second and a third patient. We know in average there is about three to five FSGS patients in a nephrology practice. So over time, you will see further deepening. But early in the launch, you want to broaden the base and getting as much prescribers as possible, build that experience, and then you will see the deepening, and that is exactly what we see in IgA nephropathy, for example.

Maury Raycroft
Biotech Analyst, Jefferies

Got it. Yeah, I guess you mentioned some numbers there, but just as far as quantifying and characterizing the pool of identified FSGS patients that doctors are actively considering for FILSPARI, is there a way to quantify that rather than the broader eligible population?

Peter Heerma
Chief Commercial Officer, Travere Therapeutics

Yes, it is a good question, and I think in particular within the context of our broad label. So FILSPARI got approval for FSGS independent of the cause. So that includes different segments, for example, primary FSGS, secondary FSGS for unknown cause, genetic FSGS, and then additionally, we also have the pediatric indication for patients eight years and older. So a broad label. What we saw in the beginning of the first quarter, so the second quarter this year, is that we had relatively high proteinuria levels. That is exactly what you said. Coming back to my earlier point, often the physicians start with the patient they are most concerned about, that is most progressive, and they will get that experience over time. But overall, I would say we see good utilization across the different segments.

I think maybe good to outline as well, this is a market that we see as over 30,000 patients addressable in the U.S. today. If, for example, secondary FSGS, I mentioned, is a patient category that often a biopsy is not being done because historically, those patients were expected FSGS, but it wouldn't change the treatment, so the confirmatory biopsy was not done. That's a segment that I see a significant growth opportunity over time as more patients will be biopsied.

Maury Raycroft
Biotech Analyst, Jefferies

Got it. I guess as far as enhancing biopsy use, is that something that you guys have any influence on?

Peter Heerma
Chief Commercial Officer, Travere Therapeutics

You know what? I think overall, this is a phenomenon you start see happening, in particular in IgA nephropathy, because there has been so much noise over the last few years. I think the scientific understanding of IgA nephropathy is much better nowadays. Based on the guidelines that was published actually a year ago, a little over a year ago, the global KDIGO guidelines, they have now a much more ambitious proteinuria target of 0.5 or preferably 0.3, while historically it was one. For FSGS, we don't have those guidelines yet, but you have, for example, a medium like UpToDate in the U.S. that many nephrologists are using, and there it's also described that basically you want to get patients to full remission, full proteinuria remission. With FILSPARI, they have now a tool to get to those ambitious targets.

Maury Raycroft
Biotech Analyst, Jefferies

Got it. Okay. At third quarter, you said IgAN PSFs declined sequentially on seasonality. What specific metrics such as new prescriber adds, new patient adds, or the less than 1.5 g segment growth or persistence declined?

Peter Heerma
Chief Commercial Officer, Travere Therapeutics

Yeah, I would say two things. I mean, I did indeed mention that there was a slight decline from the second quarter to the third quarter. That doesn't worry me. That's a typical phenomenon you see in the third quarter because you have the summer seasonality, and we know that less IgA nephropathy patients see their physician in that time. But I'm excited how we continue to add new prescribers to the mix for IgA nephropathy, and we also further deepen the pool of physicians that already have experience with FILSPARI. So, I would say it remains a very healthy business, but this is a very dynamic market, and in a dynamic market, you may see more variability.

Maury Raycroft
Biotech Analyst, Jefferies

Yeah. Yeah, makes sense. But nothing concerning with the third quarter?

Peter Heerma
Chief Commercial Officer, Travere Therapeutics

No, I think overall, and especially coming from ASN a few weeks ago, I met with a lot of nephrologists, and I think the story of FILSPARI, the positioning, I think is very well established, and that's reinforced also by the global guidelines that was published last year.

Maury Raycroft
Biotech Analyst, Jefferies

Right. Okay. Peter, you noted approximately 70% of IgAN patients below 1.5 g is your largest market share. What is your current penetration of that segment, and what penetration in IgAN would get you to $1 billion in sales?

Peter Heerma
Chief Commercial Officer, Travere Therapeutics

Yeah, it's a good question. I would say overall, about 70% of the IgA nephropathy patients have proteinuria, elevated proteinuria, but below 1.5 g. That's a significant opportunity for FILSPARI, and often physicians start in that patient population with FILSPARI, replacing the RAS inhibitor that has not been effective over time, and FILSPARI is the better option there. We see a great opportunity to continue to penetrate that particular market. I think patient with higher proteinuria, there may be with the additional options that you have available, some physicians may choose either to go in combination, FILSPARI with, for example, a B-cell, or if they would go for initially for a B-cell, we know that many of those patients have remaining high proteinuria levels, and I think that was published recently in one of the B-cell manuscript at ASN. Also there, you continue to have an opportunity.

I think the bigger opportunity, the 70% of the patients below 1.5 g, but also patients with higher proteinuria levels, remains some opportunity for FILSPARI.

Maury Raycroft
Biotech Analyst, Jefferies

Going like specific penetration, you're not going to provide—

Peter Heerma
Chief Commercial Officer, Travere Therapeutics

We haven't disclosed particular numbers on now penetration, no.

Maury Raycroft
Biotech Analyst, Jefferies

Okay.

Chris Cline
CFO, Travere Therapeutics

I think, Maury, the one thing that we have highlighted is that we believe that there are more than 100,000 patients out there overall for IgAN and FSGS. Cumulative PSFs to date, or cumulative new patient start forms, have been about 11%. That should tell you that you have a long ways to go in terms of penetration for both IgAN and FSGS.

Maury Raycroft
Biotech Analyst, Jefferies

Got it. Makes sense. You commented on some one-time events in third quarter that could have an impact on fourth quarter. Can you remind us of what those were and expectations for the end of the year?

Chris Cline
CFO, Travere Therapeutics

Sure. Again, as Peter mentioned, a very strong third quarter. The two things that we did highlight as one-time events, one would be an increase in inventory at one of our specialty pharmacies. I think this was a product of them catching up to the increase, a significant increase in demand that we saw with the launch of FSGS. Our expectation is that they will work down that inventory in the fourth quarter, and that is about $8 million that we think was pulled from 4Q into 3Q. We do not have control over their ordering patterns ultimately, so it will be up to them, but that is our expectation.

We did have a $2 million true-up on gross-to-nets that was a benefit in the third quarter. What we highlighted is that in the fourth quarter, we do expect our gross-to-nets to be a bit wider than they were in the third quarter or the second quarter. That is typical in the fourth quarter as you are accruing for the channel at the beginning of the year. Also, as we have a greater proportion of FSGS patients coming onto therapy, there is a slightly different mix. In IgA nephropathy, we have about 70/30 commercial to CMS split. In FSGS, we expect that to still be predominantly commercial, but a little bit more CMS mix, and so that is going to have a bit of a higher gross-to-net as we go forward there.

Maury Raycroft
Biotech Analyst, Jefferies

Got it. Makes sense. You are more recently saying that you can achieve greater than $3 billion peak sales by 2033. What are the key underlying assumptions to get you to this goal?

Chris Cline
CFO, Travere Therapeutics

Sure. The peak, it's not actually peak sales, it's now $3 billion by 2033, and that's an important distinction because we had previously stated that our expected LOE was 2033, and now with additional patents, we believe that we can go beyond that. We still believe that we can reach $3 billion in annual sales from FILSPARI by that year. What's driving that is going back to what I mentioned about the more than 100,000 patients that are out there with IgA nephropathy and FSGS, and being in the early innings of penetration there. I think Peter and his team have done an excellent job of building a foundational position for FILSPARI and IgA nephropathy, and we've commented there that that market alone can be greater than $1 billion for FILSPARI.

Then we've mentioned that FSGS can be much larger, and that's an area where you have more than 30,000 patients, and we expect that number to grow, as Peter mentioned, when you see greater biopsy rates, earlier treatment intervention, and ultimately, we're the only treatment available for FSGS for some time. Our goal is to reach as many patients as we can, and I think we're on a great trajectory to get to that figure by 2033.

Maury Raycroft
Biotech Analyst, Jefferies

Got it. Makes sense. Our understanding is that FILSPARI should be complementary rather than directly competing with immunomodulating therapies. Feedback at ASN was favorable toward BAFF/APRILs. How do you expect the utilization of these two classes of medicines will evolve?

Peter Heerma
Chief Commercial Officer, Travere Therapeutics

Yeah, I think it will be very consistent how physicians have treated in the past, by treating both the kidney as well as the immune system. Maybe the best way to describe that is when I met with the chair of the global KDIGO guidelines a few years ago. He said to me, "When I talk to an IgA nephropathy patient, a newly diagnosed IgA nephropathy patient, I tell them, 'You basically have two diseases. You have a kidney disease, and you have an an immune-mediated disease.' And we have to treat them both, and we have to treat them both in the most aggressive way." If you think historically, you had the RAS inhibitors, the ACE inhibitors, and the ARBs within the kidney-targeted medicine, and you had the steroids in the immune-mediated approach. Now you have FILSPARI as a superior treatment option versus RAS inhibition.

For those patients that are needing it, you have B-cells or complement inhibitors. You have alternative options now for immune-mediated approaches.

Maury Raycroft
Biotech Analyst, Jefferies

Yeah, that makes sense. What percent of your current IgAN base is now on FILSPARI plus BAFF/APRIL combo?

Peter Heerma
Chief Commercial Officer, Travere Therapeutics

Yeah, I would say the APRIL/BAFF is still fairly new in the marketplace. I have heard about combination therapy. We've seen it in the past as well, for example, with Fabhalta in the past, FILSPARI plus Fabhalta. Even before that, you had FILSPARI plus Tarpeyo. So we have seen combination use in the past. What I'm hearing from physicians that a significant part of the B-cell prescriptions is on top of FILSPARI.

Maybe good to outline a large portion of patients that go on FILSPARI. It is the first branded therapy. It is the first novel therapy. If you look at that for B-cell, it is a significant lower part. It is basically half what FILSPARI is doing. I think that kind of describes how physicians are thinking about it. I think it is exciting for patients that there are multiple options, because I believe in this day and age, IgAN patients do not have to see the dialysis chair anymore, and that is a significant improvement. We know from the past, from the RaDaR study, that a significant amount of patients did progress to dialysis ultimately.

Maury Raycroft
Biotech Analyst, Jefferies

Got it. Makes sense. For the patients on Tarpeyo or Fabhalta, like in the past, it is probably a small proportion of your patients that are on combos then?

Peter Heerma
Chief Commercial Officer, Travere Therapeutics

So far, yes. I think over time, I am expecting that you will see more combination therapy. I mentioned earlier the KDIGO guidelines for IgAN that was published in September last year. They require a much more ambitious treatment target. Historically, that was 1 g per gram. Now it is 0.5 g or preferably 0.3 g. That is a 50%-70% reduction of what the target was in the past. Many patients will not get to those levels by one mechanistic approach. I think there is a complementary nature there, and I do expect that you will start to see more combination over time.

Maury Raycroft
Biotech Analyst, Jefferies

Got it. If BAFF/APRIL therapies take meaningful share of IgAN patient starts, how much new patient share does FILSPARI need to retain to support continued growth to get to your peak projections at a similar rate in IgAN, assuming consistent duration and persistence?

Peter Heerma
Chief Commercial Officer, Travere Therapeutics

Yeah, I would say to Chris's earlier point, the fundamentals of the IgA nephropathy business is very strong for FILSPARI. Like I said, physicians understand the positioning. Physicians understand that this is not competing with immune-mediated therapies, but it is complementary. And FILSPARI has a very strong position by the only medicine that actually has shown superiority versus an active maximally dosed therapy, a RAS inhibitor. So I think the fundamentals remain strong, and so I am confident that the $3 billion in 2033 is a reasonable goal.

Maury Raycroft
Biotech Analyst, Jefferies

Got it. Okay. Chris, you mentioned the patents earlier potentially extending the opportunity beyond 2033. Can you talk about that and how that impacts your view of the deal?

Chris Cline
CFO, Travere Therapeutics

Yeah. So earlier this year, we had two patents that we have been working on, one for uses of FILSPARI in IgA nephropathy and one for uses in FSGS that we were prosecuting through the pathway in the U.S. And we had earlier this year the IgAN patent granted, and it has since been listed into the Orange Book. And we recently had the FSGS patent allowed by the USPTO, and we are in the process of getting that granted and will ultimately get that listed in the Orange Book as well. The date for both of those is into 2037. So, prior to those patents being prosecuted, we had had an LOE of around 2033 or into 2033.

And so we believe that this puts us in a much stronger position to be able to continue growing FILSPARI and helping patients well beyond 2033, and look forward to providing updates on some additional patent work in the future.

Maury Raycroft
Biotech Analyst, Jefferies

Got it. Okay. For that additional patent work, you're not saying much more on that?

Chris Cline
CFO, Travere Therapeutics

Not at this point.

Maury Raycroft
Biotech Analyst, Jefferies

Yeah. Okay. Let's shift gears. Let's talk about HCU. For pegtibatinase in HCU, how's the phase III HARMONY enrollment tracking? Maybe talk about the screen failure rate that you're seeing in the study.

Chris Cline
CFO, Travere Therapeutics

Sure. Maybe if I take a step back and talk a little bit about the opportunity with HCU. HCU is a rare metabolic disease where, unfortunately, you have clinical outcomes in teenagers and people in their young 20s and 30s that have eye lens dislocation, cognitive impairment, and life-threatening ischemic events like heart attack and stroke. This is caused by a toxic accumulation of total homocysteine that builds up over time due to a defect in the CBS enzyme. With pegtibatinase, we're directly addressing that lost enzyme activity. What we've seen to date has been extremely compelling from our phase I/II COMPOSE study. That gave us the confidence to move into a pivotal phase III study that, the HARMONY study, as you mentioned, global study, that is doing quite well in enrollment.

Here we are enrolling more than 70 patients, and we are doing quite well and expected on track to have data in the second half of next year.

Maury Raycroft
Biotech Analyst, Jefferies

Got it. And in the phase I/II study, you showed a 67% reduction in plasma total homocysteine at 12 weeks. What treatment effect is the phase III powered to detect, and what magnitude of reduction do you think would be both clinically meaningful and sufficient for approval?

Chris Cline
CFO, Travere Therapeutics

Sure. When you think about clinical meaningful, we often hear roughly 20%-30%, but more often, I think physicians will focus on getting patients below key thresholds of micromoles. So, physicians really seek to get patients below 100 micromoles of total homocysteine because that is really when they start to believe that you are at a lower risk of some of the clinical outcomes that I just mentioned. And they will also look to getting patients below 50 micromoles in order to consider potentially introducing additional protein to their diet. And similar to rare kidney disease, where you are looking to get proteinuria as low as you can, really the goal is to get total homocysteine as low as you can. So what we have seen so far in our phase I/II is the ability at the high dose to get patients all the way down 67% on average.

Importantly, all patients in those higher doses achieved a threshold below 100 or got below 100 micromoles. We saw some patients get below 50 and actually saw the first patient get into a normal range. So very encouraging results there. If we can come anywhere near those data in the phase III, we will be very well-powered to show that difference. What we tried to do with the phase III was really set it up so that it would be in a good position to replicate what we saw in phase I/II. We made two slight adjustments that I think are actually going to be helpful. The first one is we introduced a diet standardization protocol, and this is really aimed at patients being able to work with a nutritionist and identify a plan for how much protein they will eat through the whole double-blind period.

Patients, if they change their diet, have different levels of protein on any given day, can affect the total homocysteine readings. This should create a standardization that avoids some of that variability. The second thing is that we introduced an open-label extension that is going to look at the potential to introduce protein if patients can get below some of the thresholds that I mentioned. We will have some of the first data coming out from this study that tells us the benefit of not only pegtibatinase, but then the ability to potentially have more protein entered into their diet. We know that that is critical for patients as living daily with a low-protein diet that is hard to get, tastes awful, is expensive, and creates social challenges is important to patients.

Maury Raycroft
Biotech Analyst, Jefferies

The diet liberalization, that adds a little bit of risk to the study, but with the 67%, you are probably powered for something lower than that. Is like 40%-50% kind of where you are?

Chris Cline
CFO, Travere Therapeutics

Maybe in the first part, for the diet liberalization side of things, that is separate from the double-blind. I would not think of that as competing or putting any kind of risk on the—

Maury Raycroft
Biotech Analyst, Jefferies

Phase III

Chris Cline
CFO, Travere Therapeutics

—the double-blind period for the primary endpoint. The primary endpoint really is looking at the reduction in total homocysteine levels from week six to 12, the average of that, and then we will follow patients in the double-blind period for 24 weeks for safety and durability. The diet liberalization or the potential to introduce protein, that is really separate, and that is something that we would hope to generate data on while we are in discussions for the BLA. But I would not look at that as having any kind of risk on the primary endpoint.

Maury Raycroft
Biotech Analyst, Jefferies

Got it.

Chris Cline
CFO, Travere Therapeutics

If we see 40%-50% reduction, I think that you would have a strong response in the study.

Maury Raycroft
Biotech Analyst, Jefferies

Got it. Okay, that is helpful. Beyond lowering homocysteine, I guess what would you want to see on the diet liberalization, and how important is that for just the product profile and pricing?

Chris Cline
CFO, Travere Therapeutics

Yeah, I don't think it is a gating factor for being able to have a successful product for patients. At the end of the day, this is a disease, would be the only disease-modifying therapy for classical homocystinuria, and there's nothing else even in the clinic at the moment. We do know that one of the biggest burdens, as I mentioned before, is adhering to a very challenging diet and the social aspects that come along with that. This will be the first time that we're really studying it with some rigor, and it'll be the first time we'll see what that potential is with pegtibatinase.

If we can show even the ability to introduce a higher protein meal even once a week or once a month, I think that that's a step forward for patients, and we're looking forward to seeing what those data tell us.

Maury Raycroft
Biotech Analyst, Jefferies

Got it. Let's shift gears, talk about your BTK inhibitor, civorebrutinib. Following the year-end IND and bridging PK/PD work, what is the development path in PMN, and can you move directly into a pivotal study, and are you leaning toward monotherapy or adding civorebrutinib on top of standard care?

Chris Cline
CFO, Travere Therapeutics

Sure. Civorebrutinib, or civo, we're very excited about. We look at it as a more selective approach to inhibiting the B-cell pathway, and really, civo has properties that we believe can be best in class from a BTK perspective. As you mentioned, one of the first areas that we're looking is PMN. We're also looking at civorebrutinib for immune-mediated FSGS and MCD, and we'll also explore additional indications beyond that. What got us originally excited were the data from the PMN study, and in that phase I/II, you see that civorebrutinib, or patients receiving civorebrutinib, had about a 90% reduction in anti-PLA2R, followed by an 80% reduction in proteinuria. A very compelling response there. Our goal now, because most of this development has been done outside of the United States, is to open and clear an IND so that we can do some dosing work.

The dosing work really is meant to be bridging and some optimization that we're going to explore. Then we'll go and we'll meet with FDA because there hadn't been any prior FDA engagement before we had in-licensed the product, and align on what the regulatory pathway looks like. The goal really is to move forward into late-stage studies. We haven't yet said whether that's pivotal or something else, but you can see a scenario where you've got the data that you need in phase I/II here to have a lot of confidence moving into pivotal study. Our goal really is to move into multiple late-stage studies in those indications that I mentioned in the not-too-distant future. In terms of specific trial design, we'll hold off on that until we have a chance to align with FDA.

I think in the precedent studies that have been done, you've seen that on top of background ACE/ARB. Again, we'll evaluate that here as we go forward and have our discussions with FDA.

Maury Raycroft
Biotech Analyst, Jefferies

Got it. Maybe talk about the balance sheet. As it strengthens, how should we think about BD becoming a larger part of the strategy, and is there a perspective on how the new CEO could approach this?

Chris Cline
CFO, Travere Therapeutics

Sure. Maybe on the last part first, I'll let Bradley comment on that once he starts. He starts on December 1st, and we're very much so looking forward to him joining. From a balance sheet perspective, we're in excellent shape. At the end of the last quarter, we had $472 million in cash on the balance sheet. We have a growing revenue stream that was nearly 100% growth year-over-year, and we expect, from a commercial perspective, to have considerable growth in the near and long term. So, a clear pathway to profitability and being able to support all of our current programs, and in very good shape.

Maury Raycroft
Biotech Analyst, Jefferies

For the timeline to get to profitability, is there anything more you are saying?

Chris Cline
CFO, Travere Therapeutics

We haven't given anything on that yet. We are in the midst of doing our budgeting process now, and we do still have investments that we need to make. Pegtibatinase is going to be enrolling and have a fully enrolled study that is running all next year. We have got to do the manufacturing to get the supply up to scale for commercial launch, and we are going to be moving civo into potentially multiple late-stage studies. There are investments to make. Even with the growth that we are expecting with the revenue side, we have got a very clear pathway.

Maury Raycroft
Biotech Analyst, Jefferies

Got it. Thanks so much for joining us today, Chris and Peter.

Chris Cline
CFO, Travere Therapeutics

Thank you for having us.